SECONDARY STRUCTURE AND TOPOLOGY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN DETERMINED BY HETERONUCLEAR 3-DIMENSIONAL NMR-SPECTROSCOPY

被引:39
作者
STOCKMAN, BJ [1 ]
SCAHILL, TA [1 ]
ROY, M [1 ]
ULRICH, EL [1 ]
STRAKALAITIS, NA [1 ]
BRUNNER, DP [1 ]
YEM, AW [1 ]
DEIBEL, MR [1 ]
机构
[1] UPJOHN CO, DIV CHEM, KALAMAZOO, MI 49007 USA
关键词
D O I
10.1021/bi00138a001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin-1 (IL-1) proteins, such as IL-1-beta play a key role in immune and inflammatory responses. Interaction of these cytokines with the IL-1 receptor induces a variety of biological changes in neurologic, metabolic, hematologic, and endocrinologic systems. Interleukin- 1 receptor antagonist protein (IRAP) is a naturally occurring inhibitor of the interleukin-1 receptor. The 153-residue protein binds to the receptor with an affinity similar to that of IL-1-beta but does not elicit any physiological responses. As a first step toward understanding IRAP's mode of action, we have used multidimensional, heteronuclear NMR spectroscopy to determine the antagonist's solution secondary structure and global fold. Using a combination of 3D H-1-N-15 NOESY-HMQC and TOCSY-HMQC and 3D H-1-N-15-C-13 HNCA and HN(CO)CA experiments on uniformly N-15- or doubly C-13/N-15-enriched IRAP, we have made resonance assignments for more than 90% of the main-chain atoms. Analysis of short- and long-range NOE's indicates that IRAP is predominantly beta-sheet, with the same overall topology as IL-1-beta but with different regions of the primary sequence comprising the beta-strands. Two short helical segments also were identified. The 14% sequence identity between IL-1-beta and IRAP increases to 25% when differences in the locations of secondary structure elements in the primary sequences are taken into account. Still, numerous differences in side chains, which ultimately play a major role in receptor interaction, exist. Comparison of the structure of IRAP with that of IL-1-beta provides a basis for understanding the structure/function relationships at the molecular level that account for the drastically different physiological effects of these two proteins.
引用
收藏
页码:5237 / 5245
页数:9
相关论文
共 38 条
[1]   INTERLEUKIN-1 RECEPTOR ANTAGONIST - A NEW MEMBER OF THE INTERLEUKIN-1 FAMILY [J].
AREND, WP .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1445-1451
[2]  
BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573
[3]   COMPARISON OF DIFFERENT MODES OF 2-DIMENSIONAL REVERSE-CORRELATION NMR FOR THE STUDY OF PROTEINS [J].
BAX, A ;
IKURA, M ;
KAY, LE ;
TORCHIA, DA ;
TSCHUDIN, R .
JOURNAL OF MAGNETIC RESONANCE, 1990, 86 (02) :304-318
[4]   NATURAL ABUNDANCE N-15 NMR BY ENHANCED HETERONUCLEAR SPECTROSCOPY [J].
BODENHAUSEN, G ;
RUBEN, DJ .
CHEMICAL PHYSICS LETTERS, 1980, 69 (01) :185-189
[5]   TOWARD COMPLETE H-1-NMR SPECTRA IN PROTEINS [J].
BROWN, SC ;
WEBER, PL ;
MUELLER, L .
JOURNAL OF MAGNETIC RESONANCE, 1988, 77 (01) :166-169
[6]   PURIFICATION, CLONING, EXPRESSION AND BIOLOGICAL CHARACTERIZATION OF AN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN [J].
CARTER, DB ;
DEIBEL, MR ;
DUNN, CJ ;
TOMICH, CSC ;
LABORDE, AL ;
SLIGHTOM, JL ;
BERGER, AE ;
BIENKOWSKI, MJ ;
SUN, FF ;
MCEWAN, RN ;
HARRIS, PKW ;
YEM, AW ;
WASZAK, GA ;
CHOSAY, JG ;
SIEU, LC ;
HARDEE, MM ;
ZURCHERNEELY, HA ;
REARDON, IM ;
HEINRIKSON, RL ;
TRUESDELL, SE ;
SHELLY, JA ;
EESSALU, TE ;
TAYLOR, BM ;
TRACEY, DE .
NATURE, 1990, 344 (6267) :633-638
[7]   HIGH-RESOLUTION 3-DIMENSIONAL STRUCTURE OF INTERLEUKIN-1-BETA IN SOLUTION BY 3-DIMENSIONAL AND 4-DIMENSIONAL NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY [J].
CLORE, GM ;
WINGFIELD, PT ;
GRONENBORN, AM .
BIOCHEMISTRY, 1991, 30 (09) :2315-2323
[8]   COMPARISON OF THE SOLUTION NUCLEAR-MAGNETIC-RESONANCE AND X-RAY CRYSTAL-STRUCTURES OF HUMAN RECOMBINANT INTERLEUKIN-1-BETA [J].
CLORE, GM ;
GRONENBORN, AM .
JOURNAL OF MOLECULAR BIOLOGY, 1991, 221 (01) :47-53
[9]   H-1 AND N-15 RESONANCE ASSIGNMENTS OF OXIDIZED FLAVODOXIN FROM ANACYSTIS-NIDULANS WITH 3D NMR [J].
CLUBB, RT ;
THANABAL, V ;
OSBORNE, C ;
WAGNER, G .
BIOCHEMISTRY, 1991, 30 (31) :7718-7730
[10]  
DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]